Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects

NCT01856426 is registered in ClinicalTrials.gov with Enanta Pharmaceuticals, Inc as lead sponsor.

NCT NCT01856426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01856426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects
Lead sponsor
Enanta Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2013
Completion date
October 31, 2015
Enrollment
28 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c